Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.
Swapnil Gupta, Joao P De Aquino, Deepak C D'Souza, Mohini Ranganathan
Psychopharmacology September 1, 2019 DOI: 10.1007/s00213-019-05235-x via PubMed
Summary
AI-generated from the abstractIn healthy individuals who respond to THC, pre-treatment with the antipsychotic haloperidol reduces the psychosis-like effects of THC. Among 10 THC responders, THC-induced increases in positive symptoms (measured by the PANSS) were lower after haloperidol (average increase of 1.1 points) than after placebo (average increase of 2.9 points). This suggests that dopamine signaling may play a role in the psychosis-like effects of cannabinoids.
Study at a glance
| Characteristics | Double-blind, placebo-controlled, within-subject experimental study Peer reviewed |
|---|---|
| Sample size | 10 |
| Population | Healthy individuals who responded to THC (increase of at least one point on PANSS positive scale) |
| Intervention | Haloperidol |
| Dose | 0.057 mg/kg oral haloperidol; 0.0286 mg/kg intravenous THC |
| Keywords | Antipsychotic Cannabinoid Dopamine Haloperidol Psychosis |
| Key finding | Haloperidol pre-treatment reduced THC-induced increases in PANSS positive scores in THC responders. |
Abstract
Δ-9-Tetrahydrocannabinol (Δ-9-THC) produces psychotomimetic effects in humans. However, the role of dopamine signaling in producing such effects is unclear. We hypothesized that dopaminergic antagonism would reduce the psychotomimetic effect of Δ-9-THC. The objective of this study was to evaluate whether pre-treatment with haloperidol would alter the psychotomimetic and perceptual-altering effects of Δ-9-THC, measured by the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) and the Clinician-Administered Dissociative Symptom Scale (CADSS) in humans. In a two-test-day double-blind study, 28 healthy individuals were administered with active (0.057 mg/kg) or placebo oral haloperidol, followed 90 and 215 min later by intravenous administration of active (0.0286 mg/kg) Δ-9-THC and placebo, respectively. This secondary analysis was conducted because of the observation in other studies and in our data that a significant proportion of individuals may not have an adequate response to THC (floor effect), thus limiting the ability to test an interaction. Therefore, this analysis was performed including only responders to THC (n = 10), defined as individuals who had an increase of at least one point on the PANSS positive scale, consistent with prior human laboratory studies. In the 10 responders, Δ-9-THC-induced increases in PANSS positive scores were significantly lower in the haloperidol condition (1.1 + 0.35) compared with the placebo condition (2.9 + 0.92). This responder analysis showed that haloperidol did reduce the psychotomimetic effect of Δ-9-THC, supporting the hypothesis that dopaminergic signaling may participate in the psychosis-like effects of cannabinoids.